Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
AssigneePrecision Medicine Holdings Pty Ltd
InventorsStephanie Fryar-Williams, Graeme Tucker
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for diagnosing a psychotic disorder, such as schizophrenia, schizoaffective disorder or psychosis, predicated on a determination of a methylation phenotype of the subject based in part on the identity of a specific polymorphism in the MTHFR gene and the analysis of a suite of biomarkers and other functional measures and indices. Also provided herein are methods for predicting prognosis and functional outcomes for subjects having a psychotic disorder, and for treating subjects having a psychotic disorder.
Claims20
A method for diagnosing a psychosis phenotype in a subject with a psychotic disorder, the method comprising:
- (a) obtaining one or more biological samples from said subject, and
- (b) determining the status of the C677T polymorphism of the MTHFR gene from the one or more biological samples,
- wherein
- (i) the presence of the homozygous CC genotype at position 677 of the MTHFR gene is indicative of an under-methylating psychosis phenotype,
- (ii) the presence of the homozygous TT genotype at position 677 of the MTHFR gene is indicative of a low activity MTHFR enzyme and an over-methylating psychosis phenotype, and
- (iii) the presence of the heterozygous CT genotype at position 677 of the MTHFR gene is indicative of a mixed-methylation psychosis phenotype.
2-26. (canceled)
A method for diagnosing a psychotic disorder, optionally schizophrenia, schizoaffective disorder or psychosis, in a subject, the method comprising:
- (a) obtaining one or more biological samples from said subject,
- (b) determining levels of one or more biomarkers, and optionally the ratios of selected biomarkers, in the one or more biological samples, and/or measuring or assessing one or more additional parameters, and
- (c) optionally comparing determined, measured or assessed levels, values or ratios from (b) with corresponding control levels, values or ratios from one or more individuals known not to suffer from the psychotic disorder,
- wherein the status of the C677T polymorphism of the MTHFR gene in the subject is known, or is determined from the one or more biological samples, and wherein
- (i) the presence of the homozygous CC genotype at position 677 of the MTHFR gene is indicative of an under-methylating psychosis phenotype,
- (ii) the presence of the homozygous TT genotype at position 677 of the MTHFR gene is indicative of a low activity MTHFR enzyme and an over-methylating psychosis phenotype, and
- (iii) the presence of the heterozygous CT genotype at position 677 of the MTHFR gene is indicative of a mixed-methylation psychosis phenotype.
A method for predicting or determining expected duration of illness or prognosis of a subject with a psychotic disorder, the method comprising:
- (a) obtaining one or more biological samples from said subject,
- (b) determining the status of the C677T polymorphism of the MTHFR gene and the psychosis phenotype,
- (c) determining levels of one or more biomarkers, and optionally the ratios of selected biomarkers,
- (d) measuring or assessing one or more additional parameters, and
- (e) determining expected duration of illness or prognosis from an analysis of said determined, measured or assessed biomarkers and additional parameters.
Dependencies are inferred from the claim text.